Description du projet
En finir avec le délai de diagnostic de l’endométriose
L’endométriose est l’une des maladies chroniques les plus courantes chez les femmes fertiles, elle touche 14 millions de femmes dans l’UE. Cette maladie est causée par la présence de tissus de l’utérus se développant principalement dans le bas-ventre. Les symptômes les plus courants sont des douleurs intenses pendant les règles et les rapports sexuels, ainsi que des douleurs pelviennes chroniques. Toutefois, il faut des années pour que la maladie soit correctement diagnostiquée, et les femmes atteintes sont plus exposées au risque de développer un cancer des ovaires que le reste de la population féminine. Le projet TRENDO, financé par l’UE, s’attaquera aux principaux problèmes liés au diagnostic et au traitement de l’endométriose. Rassemblant des experts en sciences cliniques et translationnelles et des partenaires industriels de six pays européens et sud-américains, le projet mettra au point des biomarqueurs et des tests non invasifs, qui permettront de raccourcir les délais de diagnostic et de réduire l’inégalité d’accès à des soins de santé coûteux.
Objectif
Endometriosis is a sever disease affecting 10% of reproductive age women, characterized by the presence of endometrial-like tissue outside of uterus. Due to the associated pain, inertility and a small, but increased risk for developing ovarian cancer, its socioeconomic impacts are considerable, and have a profound effect on women’s mental and physical health. Endometriosis is characterized by a diagnostic delay of a decade, as its diagnosis is surgery-based, and all attempts to identify the non-invasive biomarkers have not been progressed beyond the discovery. Moreover, current treatments include only surgery or hormonal medications with significant side effects. In view of the above, the endometriosis care is challenging, and is hampered by the considerable heterogeneity of clinical manifestations. TRENDO consortium addresses the main problems in endometriosis diagnosis and therapy in a multidisciplinary and trans-sectoral effort, bringing together the clinical and translational science experts, and industry partners from six European and South American countries. We develop non-invasive biomarkers and testing, which shorten the diagnostic delay, and reduce the unequal access to expensive healthcare. These biomarkers are tested for the suitability as drug targets, to monitor treatment response, and to predict the personalized clinical recommendations. By combining the strengths of our partners, we provide novel tools addressing the most urgent priorities in endometriosis and to successfully translate our findings into novel therapeutic approaches. This challenging scientific task provides an ideal career-enhancing setting for young scientists, providing them with transdisciplinary and trans-domain training, and with essential transferable skills. The training program provides a new generation of researchers with a strong competitive advantage on the job market and increase European academic and industry competence in one of the under-investigated clinical domains.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Coordinateur
48149 MUENSTER
Allemagne